Aliases & Classifications for Dysautonomia

MalaCards integrated aliases for Dysautonomia:

Name: Dysautonomia 54 29 55 6 73

Classifications:



External Ids:

UMLS 73 C0013363

Summaries for Dysautonomia

NINDS : 54 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Dysautonomia is related to neuropathy, hereditary sensory and autonomic, type iii and parkinson disease, late-onset. An important gene associated with Dysautonomia is ELP1 (Elongator Complex Protein 1), and among its related pathways/superpathways is Parkinsons Disease Pathway. The drugs Lidocaine and Midodrine have been mentioned in the context of this disorder. Affiliated tissues include heart, spinal cord and brain, and related phenotypes are endocrine/exocrine gland and skeleton

Wikipedia : 76 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Dysautonomia

Diseases in the Dysautonomia family:

Dysautonomia-Like Disorder

Diseases related to Dysautonomia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 neuropathy, hereditary sensory and autonomic, type iii 34.0 ACTL7B ELP1
2 parkinson disease, late-onset 30.5 GBA SNCA SNCAIP
3 movement disease 29.1 GBA SNCA
4 autosomal dominant cerebellar ataxia 28.8 PRNP SNCA
5 synucleinopathy 28.6 GBA SNCA SNCAIP
6 dementia 27.7 GBA PRNP SNCA SNCAIP
7 dysautonomia-like disorder 12.1
8 motor neuropathy, peripheral, with dysautonomia 12.0
9 acute cholinergic dysautonomia 11.9
10 pure autonomic failure 11.8
11 autonomic dysfunction 11.6
12 hereditary sensory neuropathy 11.6
13 insensitivity to pain, congenital, with anhidrosis 11.6
14 stuve-wiedemann syndrome 11.3
15 fatal familial insomnia 11.1
16 autonomic nervous system disease 11.0
17 parkinson disease 1, autosomal dominant 11.0
18 neuropathy, hereditary sensory and autonomic, type vi 10.9
19 autoimmune autonomic ganglionopathy 10.8
20 autoimmune gastrointestinal dysmotility 10.8
21 scoliosis, isolated 1 10.8
22 rigidity and multifocal seizure syndrome, lethal neonatal 10.8
23 primary orthostatic hypotension 10.8
24 postural hypotension 10.8
25 parkinson disease 23, autosomal recessive early-onset 10.8
26 neuropathy 10.2
27 brain injury 10.1
28 parkinson disease 3, autosomal dominant 10.1 SNCA SNCAIP
29 leukoencephalopathy, hereditary diffuse, with spheroids 10.1 PRNP SNCA
30 traumatic brain injury 10.1
31 neuronitis 10.1
32 hereditary late-onset parkinson disease 10.0 GBA SNCA
33 aphasia 10.0 PRNP SNCA
34 autonomic neuropathy 10.0
35 fibromyalgia 9.9
36 early-onset parkinson's disease 9.9 GBA SNCA
37 toxic encephalopathy 9.9 PRNP SNCA
38 tremor 9.9 GBA SNCA
39 polyneuropathy 9.9
40 multiple system atrophy 1 9.9
41 myopathy 9.8
42 orthostatic intolerance 9.8
43 syncope 9.8
44 diabetes mellitus 9.8
45 central nervous system disease 9.8 PRNP SNCA
46 chagas disease 9.8
47 chronic fatigue syndrome 9.8
48 sleep disorder 9.8
49 cerebritis 9.8
50 retinitis 9.8

Graphical network of the top 20 diseases related to Dysautonomia:



Diseases related to Dysautonomia

Symptoms & Phenotypes for Dysautonomia

MGI Mouse Phenotypes related to Dysautonomia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.35 ELP1 GBA LIFR PRNP SNCA
2 skeleton MP:0005390 9.02 ELP1 GBA LIFR PRNP SNCA

Drugs & Therapeutics for Dysautonomia

Drugs for Dysautonomia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 504)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
2
Midodrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
3
Bupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
5
Acetylcholine Approved Phase 4,Not Applicable 51-84-3 187
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
8
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
9
Zolpidem Approved Phase 4,Not Applicable 82626-48-0 5732
10
Furosemide Approved, Vet_approved Phase 4,Not Applicable 54-31-9 3440
11
Indapamide Approved Phase 4 26807-65-8 3702
12
Fludrocortisone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 127-31-1 31378
13
Gabapentin Approved, Investigational Phase 4,Not Applicable 60142-96-3 3446
14
Bisoprolol Approved Phase 4 66722-44-9 2405
15
Propranolol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 525-66-6 4946
16
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
17
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
18
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
19
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23651-95-8 443940
20
gamma-Aminobutyric acid Approved, Investigational Phase 4,Not Applicable 56-12-2 119
21
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 1
22
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
23
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-81-7 5785 54670067
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
25 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
28 triamcinolone acetonide Phase 4,Phase 3
29 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 abobotulinumtoxinA Phase 4,Not Applicable
31 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Adrenergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
38 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 GABA Agents Phase 4,Early Phase 1,Not Applicable
41 GABA Agonists Phase 4
42 Serotonin Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 GABA-A Receptor Agonists Phase 4
44 Serotonin Antagonists Phase 4
45 Neuromuscular Agents Phase 4,Not Applicable
46 Sympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Anesthetics, Local Phase 4,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 538)
# Name Status NCT ID Phase Drugs
1 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
2 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
3 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
4 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
5 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
6 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
7 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
8 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
9 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
10 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
11 Prophylactic Administration of Vitamin C in Wrist Fractures Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
12 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study Completed NCT02308124 Phase 4 Midodrine;Pyridostigmine Bromide;Midodrine + pyridostigmine
13 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
14 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
15 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
16 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
17 Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
18 Renal Denervation in Diabetic Nephropathy Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
19 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
20 Restore Claims Characterization Study Completed NCT00200122 Phase 4
21 High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System Completed NCT02265848 Phase 4
22 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
23 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
24 Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor Recruiting NCT03178591 Phase 4 vildagliptin;Dapagliflozin
25 Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH Recruiting NCT03350659 Phase 4 Midodrine;Atomoxetine
26 Dawn Simulation and Postural Hypotension Recruiting NCT02632318 Phase 4
27 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
28 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
29 Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Recruiting NCT03291197 Phase 4 Suprascapular and median nerve blocks
30 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Active, not recruiting NCT03098368 Phase 4 Rotigotine;Placebo
31 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
32 Brain Perfusion & Oxygenation in Parkinson's Disease With NOH Not yet recruiting NCT03229174 Phase 4 Droxidopa;Placebo
33 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4 midodrine hydrochloride (ProAmatine®)
34 Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease Unknown status NCT00629161 Phase 2, Phase 3 Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant);placebo
35 Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II) Unknown status NCT01392599 Phase 3
36 Acupuncture for Post-stroke Shoulder-hand Syndrome Unknown status NCT02011854 Phase 2, Phase 3
37 RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
38 Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block Unknown status NCT01134289 Phase 3
39 Intravenous Immunoglobulins in Complex-regional Pain Syndrome Unknown status NCT00949065 Phase 3
40 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Completed NCT01987219 Phase 3 Albuterol-sulphate;Ipratropium-bromide
41 Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Completed NCT01212484 Phase 3 Carbidopa;Placebo
42 Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. Completed NCT02063126 Phase 2, Phase 3
43 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
44 The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Completed NCT02099890 Phase 3
45 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3 Double blinded IVIg
46 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
47 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
48 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
49 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
50 Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease Completed NCT00656253 Phase 2, Phase 3 Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.);Placebo

Search NIH Clinical Center for Dysautonomia

Genetic Tests for Dysautonomia

Genetic tests related to Dysautonomia:

# Genetic test Affiliating Genes
1 Dysautonomia 29

Anatomical Context for Dysautonomia

MalaCards organs/tissues related to Dysautonomia:

41
Heart, Spinal Cord, Brain, Testes, Liver, Bone, Cortex

Publications for Dysautonomia

Articles related to Dysautonomia:

(show top 50) (show all 637)
# Title Authors Year
1
Prevalence and characteristics of sleep-disordered breathing in familial dysautonomia. ( 29680425 )
2018
2
Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia. ( 29196937 )
2018
3
A Controlled Trial of Inhaled Bronchodilators in Familial Dysautonomia. ( 29234869 )
2018
4
Severe dysautonomia as a main feature of anti-GAD encephalitis: Report of a paediatric case and literature review. ( 29370977 )
2018
5
Dysautonomia in the pathogenesis of migraine. ( 29212396 )
2018
6
Ambulatory blood pressure profiles in familial dysautonomia. ( 29435868 )
2018
7
Exon-specific U1 snRNAs improve ELP1 exon 20 definition and rescue ELP1 protein expression in a familial dysautonomia mouse model. ( 29701768 )
2018
8
Development of a clinical prediction score for detection of suspected cases of equine grass sickness (dysautonomia) in France. ( 29204821 )
2018
9
Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice. ( 29672717 )
2018
10
Characteristics of ataxic gait in familial dysautonomia patients. ( 29698477 )
2018
11
Blocking of an intronic splicing silencer completely rescues IKBKAP exon 20 splicing in familial dysautonomia patient cells. ( 29762696 )
2018
12
Equine Dysautonomia. ( 29398183 )
2018
13
Dysautonomia as Onset Symptom of Myotonic Dystrophy Type 2. ( 29533949 )
2018
14
Retina-specific loss of <i>Ikbkap/Elp1</i> causes mitochondrial dysfunction that leads to selective retinal ganglion cell degeneration in a mouse model of familial dysautonomia. ( 29929962 )
2018
15
Depression and cardiac dysautonomia in eating disorders. ( 28244034 )
2017
16
Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia. ( 28674865 )
2017
17
The familial dysautonomia disease gene<i>IKBKAP</i>is required in the developing and adult mouse central nervous system. ( 28167615 )
2017
18
Methotrexate-induced dysautonomia in a patient with rheumatoid arthritis. ( 28398506 )
2017
19
RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia. ( 28592461 )
2017
20
Pyridoxine Toxicity Small Fiber Neuropathy With Dysautonomia: A Case Report. ( 28827489 )
2017
21
<i>IKBKAP/ELP1</i> gene mutations: mechanisms of familial dysautonomia and gene-targeting therapies. ( 29290691 )
2017
22
Ipilimumab-induced Guillain-BarrAc Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy. ( 28452849 )
2017
23
Sudden Unexpected Death During Sleep in Familial Dysautonomia: A Case-Control Study. ( 28521050 )
2017
24
Alterations in amino acid status in cats with feline dysautonomia. ( 28333983 )
2017
25
Response Letter to 'Optimising physiology for adolescents with dysautonomia'. ( 28906019 )
2017
26
Founder mutation in IKBKAP gene causes vestibular impairment in familial dysautonomia. ( 29289840 )
2017
27
Transient dysautonomia in an acute phase of encephalopathy with biphasic seizures and late reduced diffusion. ( 28413125 )
2017
28
Calming the Storm: Dysautonomia for the Pediatrician. ( 28716515 )
2017
29
Pathological Confirmation of Optic Neuropathy in Familial Dysautonomia. ( 28395083 )
2017
30
Optimising physiology for adolescents with dysautonomia. ( 28477426 )
2017
31
Animal and cellular models of familial dysautonomia. ( 28667575 )
2017
32
Pure autonomic failure versus prodromal dysautonomia in Parkinsona89s disease: Insights from the bedside. ( 28164144 )
2017
33
Familial dysautonomia: a disease with hidden tears. ( 28401297 )
2017
34
Partial dysautonomia: An interesting presentation. ( 28749384 )
2017
35
BGP-15 prevents the death of neurons in a mouse model of familial dysautonomia. ( 28439028 )
2017
36
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia. ( 28404519 )
2017
37
Use of Biotronik closed loop pacemaker to treat recurrent syncope in pediatric patient with dysautonomia. ( 28491761 )
2017
38
Basic research and model systems in familial dysautonomia: What do we know and what's next? ( 28707017 )
2017
39
Psychiatric manifestations and dysautonomia at the onset of focal epilepsy in adults: Clinical signs indicating autoimmune origin. ( 27311973 )
2016
40
Axon Transport and Neuropathy: Relevant Perspectives on the Etiopathogenesis of Familial Dysautonomia. ( 26724390 )
2016
41
Twenty-four-hour blood pressure profile, orthostatic hypotension, and cardiac dysautonomia in elderly type 2 diabetic hypertensive patients. ( 27624333 )
2016
42
MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia. ( 27483351 )
2016
43
Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients. ( 27239367 )
2016
44
Prominent dysautonomia in a patient with POEMS syndrome. ( 27165541 )
2016
45
Poster 72 Teetering on the Edge: Rehabilitation in a Medically Complex Patient with Familial Dysautonomia (Hereditary Sensory Autonomic Neuropathy Type III): A Case Report. ( 27672840 )
2016
46
Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. ( 27553747 )
2016
47
Poster 257 Tizanidine Reduces Night Sweats due to Dysautonomia in Syringomyelia: A Case Report. ( 27673012 )
2016
48
Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study. ( 27129499 )
2016
49
Obstructive Sleep Disordered Breathing Is More Common than Central in Mild Familial Dysautonomia. ( 27655467 )
2016
50
Mother-induced hypertension in familial dysautonomia. ( 26589199 )
2016

Variations for Dysautonomia

ClinVar genetic disease variations for Dysautonomia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XX;inv(14)(q24.1q32.1)dn inversion Uncertain significance

Expression for Dysautonomia

Search GEO for disease gene expression data for Dysautonomia.

Pathways for Dysautonomia

Pathways related to Dysautonomia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.55 SNCA SNCAIP

GO Terms for Dysautonomia

Cellular components related to Dysautonomia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synaptic vesicle GO:0008021 9.26 SNCA SNCAIP
2 extrinsic component of membrane GO:0019898 9.16 GBA PRNP
3 postsynapse GO:0098794 8.96 PRNP SNCA
4 inclusion body GO:0016234 8.62 PRNP SNCA

Biological processes related to Dysautonomia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of protein phosphorylation GO:0001933 9.4 PRNP SNCA
2 negative regulation of neuron death GO:1901215 9.37 GBA SNCA
3 protein destabilization GO:0031648 9.32 PRNP SNCA
4 positive regulation of neuron death GO:1901216 9.26 PRNP SNCA
5 cellular response to copper ion GO:0071280 9.16 PRNP SNCA
6 regulation of neurotransmitter secretion GO:0046928 8.96 SNCA SNCAIP
7 dopamine metabolic process GO:0042417 8.62 SNCA SNCAIP

Molecular functions related to Dysautonomia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 8.96 PRNP SNCA
2 cuprous ion binding GO:1903136 8.62 PRNP SNCA

Sources for Dysautonomia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....